top of page

AusperBio Announces Major Progress in AHB-137 Clinical Development

AHB-137, empowered by AusperBio’s proprietary Med-OligoTM ASO technology platform, holds the potential as a backbone in the quest for a functional cure for CHB.

This novel dual-mechanism ASO has been evaluated in two Phase 1a/1b clinical trials in parallel, one in China and another outside China. To date, 122 participants, including 30 CHB patients, have received either single or multiple doses of AHB-137. In China (chinadrugtrials.org.cn #CTR20232098; clinicaltrials.gov #NCT06115993), enrollment of CHB patients in the 150mg and 300mg cohorts has been completed.

The study outside China (clinicaltrials.gov #NCT05717686) is also rapidly progressing in dosing of CHB patients, with 6 participants having completed 4-week dosing in the US and New Zealand.

About Chronic Hepatitis B Chronic Hepatitis B (CHB) infection is a liver disease estimated to affect nearly 290 million people worldwide and is a leading cause of major liver diseases such as liver cirrhosis and hepatocellular carcinoma. Although current treatment options can suppress HBV replication, achieving a cure is rare. Therefore, the discovery of a cure for CHB with finite treatment is a serious and urgent medical need.

Aktuelle Beiträge

Alle ansehen

mRNA-Medikament soll Lipide im Blut senken

Laut einer placebokontrollierten und doppelblinden Studie unter der Leitung von Forschern des Brigham and Women’s Hospital, einem Gründungsmitglied des Mass General Brigham-Gesundheitssystems, könnte

Comments

Couldn’t Load Comments
It looks like there was a technical problem. Try reconnecting or refreshing the page.
bottom of page